DavidAllenTaberMD

Oncology • Mishawaka, IN

Physician

Join to view full profile

Are you Dr. Taber?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 93 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
5340 Holy Cross Pkwy
Mishawaka, IN 46545
Phone+1 574-237-1328

Fax+1 574-237-1348
Is this information wrong?

Summary

Dr. David Taber, MD is an oncologist in Mishawaka, Indiana. He is currently licensed to practice medicine in Indiana. He is affiliated with Saint Joseph Health System, Memorial Hospital of South Bend, and Elkhart General Hospital.

Education & Training

Cook County Health and Hospitals SystemFellowship, Hematology and Medical Oncology, 1983 - 1985
Cook County Health and Hospitals SystemResidency, Internal Medicine, 1980 - 1983
University of Illinois College of MedicineClass of 1980

Certifications & Licensure

IN State Medical License 1989 - 2021

Clinical Trials

Decitabine in Treating Patients With Myelofibrosis Start of enrollment: 2004 Sep 29
Active, not recruiting
Phase 2
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Start of enrollment: 2006 Oct 23
Active, not recruiting
Phase 1, Phase 2
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors Start of enrollment: 2009 Mar 16
Completed
Phase 2
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy Start of enrollment: 2010 Dec 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

9 citations
Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Onco...
Heather Riggs, Shadia I. Jalal, Tareq Al Baghdadi, Sumeet Bhatia, J. B. McClean, Cynthia D. Johnson, Menggang Yu, David Taber, Wael A. Harb, Nasser H. Hanna> ;Clinical Lung Cancer. 2013 May 1
191 citations
Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma
Hedy L. Kindler, Theodore Karrison, David R. Gandara, Charles Lu, Lee M. Krug, James P. Stevenson, Pasi A. Jänne, David I. Quinn, Marianna Koczywas, Julie R. Brahmer, ...> ;Journal of Clinical Oncology. 2012 Jul 10
38 citations
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium
Manish R. Sharma, Kristen Wroblewski, Blase N. Polite, James A. Knost, James A. Wallace, Sanjiv Modi, Bethany G. Sleckman, David A. Taber, Everett E. Vokes, Walter M. ...> ;Investigational New Drugs. 2012 Jun 1
A phase II trial of neoadjuvant cisplatin (C), gemcitabine (G), and sunitinib (S) in muscle-invasive urothelial carcinoma (miUC): Results from Hoosier Oncology Group G...
Lerner SP, Powles T, Hahn NM, Gardner T, Cheng L, Green J, Berney D, Taber D, Landgraf J, Shen SS, Sonpavde G> ;J. Clin. Oncol.. 2011-05-20
Dasatinib (D) in previously treated metastatic colorectal cancer (mCRC) patients: A phase II trial of the University of Chicago phase II consortium.
Sharma M, Wroblewski K, Kozloff M, Modi SS, Sleckman BG, Taber D, Vokes EE, Stadler WM, Polite BN, Kindler HL> ;J. Clin. Oncol.. 2011-02-01
4 citations
The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium
Halla Sayed Nimeiri, D. A. Singh, Kristen Kasza, David A. Taber, Rafat Ansari, Everett E. Vokes, Hedy L. Kindler> ;Investigational New Drugs. 2010 Dec 1
55 citations
Phase II study of sunitinib malate in head and neck squamous cell carcinoma
Nicholas W. Choong, Mark Kozloff, David A. Taber, H. Shawn Hu, James L. Wade, Percy Ivy, Theodore Karrison, Allison Dekker, Everett E. Vokes, Ezra E.W. Cohen> ;Investigational New Drugs. 2010 Oct 1
Erlotinib and bevacizumab in chemotherapy-naive performance status 2 patients with advanced non-small cell lung cancer.
Al Baghdadi T, Hanna N, Bhatia S, McClean J, Johnson C, Yu M, Taber D, Harb W> ;J. Clin. Oncol.. 2009-05-20
Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Choong NW, Cohen EE, Kozloff MF, Taber D, Wade Iii JL, Hu S, Ivy SP, Nichols K, Dekker A, Vokes EE> ;J. Clin. Oncol.. 2008-05-20
Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer (NSCLC): A phase II study from the Hoosier Oncology Group.
Agarwala AK, Einhorn L, Fisher W, Bruetman D, McClean J, Taber D, Titzer M, Juliar B, Breen T, Hanna N> ;J. Clin. Oncol.. 2006-06-20
A phase II trial of the epothilone B analog BMS-247550 in patients (pts) with hepatobiliary cancer (HBC): An updated analysis.
Singh DA, Taber D, Ansari R, Lenz HJ, Agamah E, Nattam S, Wade-Oliver K, Kasza K, Vokes EE, Kindler HL> ;J. Clin. Oncol.. 2006-06-20
362 citations
Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
Hedy L. Kindler, Gregory Friberg, D. A. Singh, Gershon Y. Locker, Sreenivasa Nattam, Mark Kozloff, David A. Taber, Theodore Karrison, Abraham H. Dachman, Walter M. Sta...> ;Journal of Clinical Oncology. 2005 Nov 1
13 citations
Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.
Apurva A. Desai, Hedy L. Kindler, David A. Taber, Edem Agamah, Sridhar Mani, Kurombi Wade-Oliver, Mark J. Ratain, Everett E. Vokes> ;Cancer Chemotherapy and Pharmacology. 2005 May 13
6 citations
A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer.
Supriya Gupta, Ann M. Mauer, Christopher W. Ryan, David A. Taber, Brian L. Samuels, Gini F. Fleming> ;American Journal of Clinical Oncology. 2005 Feb 1
109 citations
Phase II Trial of PS-341 in Patients With Renal Cell Cancer: A University of Chicago Phase II Consortium Study
Nancy B. Davis, David A. Taber, Rafat Ansari, Christopher W. Ryan, Christopher George, Everett E. Vokes, Nicholas J. Vogelzang, Walter M. Stadler> ;Journal of Clinical Oncology. 2004 Jan 1
3 citations
Phase I/II investigation of paclitaxel, ifosfamide and carboplatin for advanced non-small-cell lung cancer
Ann M. Mauer, Rafat Ansari, Philip C. Hoffman, Stuart A. Krauss, David A. Taber, S. A. Tembe, G. T. Gabrys, T. Cotter, L. P. Schumm, Livia Szeto, Everett E. Vokes> ;Annals of Oncology. 2003 May 1
130 citations
Phase II Trial of Weekly Intravenous Gemcitabine With Continuous Infusion Fluorouracil in Patients With Metastatic Renal Cell Cancer
Brian I. Rini, Nicholas J. Vogelzang, Mary C. Dumas, James L. Wade, David A. Taber, Walter M. Stadler> ;Journal of Clinical Oncology. 2000 Jun 12
168 citations
Flavopiridol, A Novel Cyclin-Dependent Kinase Inhibitor, in Metastatic Renal Cancer: A University of Chicago Phase II Consortium Study
Walter M. Stadler, Nicholas J. Vogelzang, Robert J Amato, Jeffery Sosman, David A. Taber, David Liebowitz, E. E. Vokes> ;Journal of Clinical Oncology. 2000 Jan 1
5 citations
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
Nicholas J. Vogelzang, Sridhar Mani, Richard L. Schilsky, Rafat Ansari, David A. Taber, Steven N. Rhinehart, Juan C. Garcia, Steven C. Meyer, Rosemarie Mick, Bruce Bro...> ;Clinical Cancer Research. 1998 Apr 1
Join now to see all

Hospital Affiliations

Memorial Hospital of South BendSouth Bend, Indiana
Elkhart General HospitalElkhart, Indiana
Northwest Health -PorterValparaiso, Indiana
Plymouth Medical CenterPlymouth, Indiana
Saint Joseph Health SystemMishawaka, Indiana
Northwest Health - La PorteLa Porte, Indiana